Evaluating targeted therapies in older patients with TP53-mutated AML.

Abstract excerpt

Mutation of thetumor suppressor gene, TP53 (tumor protein 53), occurs in up to 15% of all patients with acute myeloid leukemia (AML) and is enriched within specific clinical subsets, most notably in older adults, and including secondary AML cases arising from preceding myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), patients exposed to prior DNA-damaging, cytotoxic therapies. In all cases,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Antineoplastic Agents
• Share to Age Factors